［1］SU ZZ，LEE SG，EMDAD L，et al．Cloning and characterization of SARI(suppressor of AP-1，regulated by IFN)［J］．Proc Natl Acad Sci USA，2008，105(52)：20906-20911．
［2］LIU J，LI J，TUO Z，et al．BATF2 inhibits PD-L1 expression and regulates CD8+T-cell infiltration in non-small cell lung cancer［J］．J Biol Chem，2023，299(11)：105302-105312．
［3］XIE JW，HUANG XB，CHEN QY，et al．m6A modification-mediated BATF2 acts as a tumor suppressor in gastric cancer through inhibition of ERK signaling［J］．Mol Cancer，2020，19(1)：114-129．
［4］ZONG Y，CHANG Y，HUANG K，et al．The role of BATF2 deficiency in immune microenvironment rearrangement in cervical cancer-New biomarker benefiting from combination of radiotherapy and immunotherapy［J］．Int Immunopharmacol，2023，126(2024)：111199-111211．
［5］CUIZ，LIN Y，HU D，et al．Diagnostic and prognostic potential of circulating and tissue BATF2 in nasopharyngeal carcinoma［J］．Front Mol Biosci，2021，8(2021)：724373-724383．
［6］PRIYADARSHINI M，MAII S，SAMAL SK，et al．SARI inhibits growth and reduces survival of oral squamous cell carcinomas(OSCC) by inducing endoplasmic reticulum stress［J］．Life Sci，2021，287（2021）：120141-120150．
［7］AGAWA H，KANEMARU H，KIMURA T，et al．BATF2 expression as a novel marker for invasive phenotype in malignant melanoma［J］．J Dermatol，2020，47(10)：e372-e373．
［8］薛龑，陈梅环，唐永金，等．SARI基因促进急性髓性白血病细胞凋亡机制的探讨［J］．中国免疫学杂志，2017，33(11)：1621-1625．
XUE Yan，CHEN Meihuan，TANG Yongjin，et al．The SARI gene promotes AML thinning exploration of the mechanism of cell apoptosis［J］．Chinese Journal of Immunology，2017，33(11)：1621-1625．
［9］薛龑，傅晓萌，郑金源，等．SARI过表达对CBFL细胞凋亡的影响及其机制［J］．中国实验血液学杂志，2019，27(4)：1020-1025．
XUE Yan，FU Xiaomeng，ZHENG Jinyuan，et al．Effect of SARI overexpression on CBFL cell apoptosis and its mechanism［J］．Chinese Journal of Experimental Hematology，2019，27(4)：1020-1025．
［10］ARBER DA，ORAZI A，HASSERJIAN R，et al．The 2016 revision to the World Health Organization classification of myeloid neoplasms andacute leukemia［J］.Blood，2016，127(20)：2391-2405.
［11］张之南，沈悌．血液病诊断与疗效标准［M］．第3版.天津：天津科学出版社，2008:131-133．
ZHANG Zhinan，SHEN Ti．Criteria for diagnosis and efficacy of blood diseases［M］．3rd edition.Tianjin：Tianjin Science Press，2008：131-133．
［12］中华医学会血液学分会白血病淋巴瘤学组．复发难治性急性髓系白血病中国诊疗指南(2017年版)［J］．中华血液学杂志,2017，38(3)：183-184．
Leukemia and Lymphoma Group of Hematology Branch of Chinese Medical Association．Chinese guidelines for the diagnosis and treatment of relapsed and refractory acute myeloid leukemia(2017 edition)［J］．Chinese Journal of Hematology，2017，38(3)：183-184．
［13］MEDINGER M，PASSWEG JR．Acute myeloid leukaemiagenomics［J］．Br J Haematol，2017，179(4)：530-542．
［14］龙心怡，胡荣.急性髓系白血病靶向治疗的研究进展［J］．现代肿瘤医学，2022，30(15):2847-2850.
LONG Xinyi,HU Rong.Research progress of targeted therapy for acute myeloid leukemia［J］．Modern Oncology，2022，30(15):2847-2850.
［15］刘洋，刘述川.不同基因突变的急性髓系白血病患者的疗效及预后研究进展［J］．现代肿瘤医学，2023，31(22):4284-4289.
LIU Yang,LIU Shuchuan.Research progress on therapeutic effect and prognosis of different gene mutations in patients with acute myeloid leukemia［J］．Modern Oncology，2023，31(22):4284-4289.
［16］张媛，黄琰，王莉华，等.免疫细胞在急性髓系白血病骨髓微环境中的浸润模式及其预后价值［J］．现代肿瘤医学，2021，29(10):1747-1752.
ZHANG Yuan,HUANG Yan,WANG Lihua,et al.Clinical relevance of tumor-infiltrating immunecells in the acute myeloid leukemia microenvironment［J］．Modern Oncology，2021，29(10):1747-1752.
［17］SHLUSH LI，MITCHELL A．AML evolution from preleukemia toleukemia and relapse［J］．Best Pract Res Clin Haematol，2015，28(2-3)：81-89.
［18］PAPAEMMANUIL E，GERSTUNG M，BULLINGER L，et al．Genomic classification and prognosis in acute myeloid leukemia［J］．N Engl J Med，2016，374(23)：2209-2221．
［19］MEDINGER M，HEIM D，HALTER JP，et al．Diagnosis and therapy of acute myeloid leukemia［J］．Ther Umsch，2019，76(9)：481-486．
［20］陈子兴．急性髓系白血病的表观遗传调控异常和表观基因组景观改变及靶向治疗研究进展［J］．中华血液学杂志，2019，40(1)：78-82.
CHEN Zixing．Progress in epigenetic deregulation and altered epigenomic landscape and targeted therapy in acute myeloid leukemia［J］．Chinese Journal of Hematology，2019，40(1)：78-82．
［21］ZSURKA G，APPEL MLT，NASTLAY M，et al．Loss of the immunomodulatory transcription factor BATF2 in humans is associated with a neurological phenotype［J］．Cells，2023，12(2)：227-241．
［22］DASH R，BHOOPATHI P，DAS SK，et al．Novel mechanism of MDA-7/IL-24 cancer-specific apoptosis through SARI induction［J］．Cancer Res，2014，74(2)：563-574．
［23］史永久，李泽，李玉中．PI3K信号通路在急性髓细胞白血病治疗及耐药性调节中作用的研究进展［J］．现代肿瘤医学，2022，30(16)：3052-3057．
SHI Yongjiu，LI Ze，LI Yuzhong．Progress in the role of PI3K signaling in the treatment and drug resistance regulation in acute myeloid leukemia［J］．Modern Oncology，2022，30(16)：3052-3057．
［24］LEONTIADOU H，GALDADAS I，ATHANASIOU C，et al．Insights into the mechanism of the PIK3CA E545K activating mutation using MD simulations［J］．Scientific Reports，2018，8(1)：15544-15560．
［25］NEPATAD I，HATFIELD KJ，TVEDT THA，et al．Clonal heterogeneity reflected by PI3K-AKT-mTOR signaling in human acute myeloid leukemia cells and its association with adverse prognosis［J］．Cancers，2018，10(9)：332-347．
［26］NEPATAD I，HATFIELD KJ，GRNNINGSTER IS，et al．The PI3K-AKT-MTOR signaling pathway in human acute myeloid leukemia(AML) cells［J］．Int J Mol Sci，2020，21(8)：2907-2929．
［27］WANG Q，LU W，YIN T，et al．Calycosin suppresses TGF-β induced epithelial-to-mesenchymal transition and migration by upregulating BATF2 to target PAI-1 via the Wnt and PI3K/Akt signaling pathways in colorectal cancer cells［J］．J Exp Clin Cancer Res，2019，38(1)：240-252．